Browse by Hotbed/Location
Filter News
Found 582,591 articles
-
BioSpace Hotbed maps have been a life sciences industry staple for over 30 years. Today the program features eight regional Hotbed Maps and the NextGen Bio Map which highlights some of the industry’s most promising startups.
-
BioSpace is proud to present its NextGen Bio “Class of 2020,” a list of up-and-coming life science companies in North America that launched no earlier than mid-2018.
-
Genelux Announces Closing of a Strategic Financing Transaction
9/26/2020
Genelux closes on first tranche of a convertible debt and warrant financing of up to $20M to fund the continued clinical development of Olvi-Vec, its lead oncolytic immunotherapy candidate [25-September-2020] SAN DIEGO , Sept. 25, 2020 /PRNewswire/ -- Genelux Corporation, a privately-held clinical-stage immunotherapy company, today announced that it has entered into a
-
MedX Health Corp. Announces Second Quarter 2020 Results
9/26/2020
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announced its results for the three and six-months ended June 30, 2020, which are also available on SEDAR ( www.sedar.com ). The Company reported revenue of $69,452 for the three months ended June 30, 2020, compared with revenue of $259,108 for the three months ended June 30, 2019. Revenue from SIAscopy™ of $31,029 for the second quarter was higher than
-
The late-stage study is part of an agreement struck between the company and the U.K. government last month that includes providing 60 million doses of the vaccine, should it be approved.
-
New York’s governor hinted he would delay distribution of a quickly approved vaccine until its safety and efficacy could be vetted by a panel of state scientists and researchers.
-
Endo International’s subsidiary, Par Sterile Products, LLC, has agreed to provide fill-finish manufacturing services to Novavax for commercial distribution of the vaccine company’s nanoparticle COVID-19 vaccine candidate.
-
The Global Cost of Containing COVID-19
9/25/2020
Even when a first vaccine is finally approved, much of the developing world currently stands to be left behind, as it was during the 2009 H1N1 pandemic. -
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 25, 2020.
-
BioSpace Movers & Shakers, Sept. 25
9/25/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers and Shakers. -
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
-
For diabetic patients, achieving a certain “time in range” is a more realistic glucose control strategy than striving for a particular daily target, according to researchers working with Sanofi who spoke during the 56th Annual Meeting of the European Association for the Study of Diabetes.
-
Starting with $30 million in seed financing in April, Taysha sprinted through a $95 million Series B in August and rounded the corner this Thursday to bring in $157 million for its IPO.
-
Schwazze, Formerly Operating as Medicine Man Technologies, Inc., to Host Investor Meetings at the Alliance Global Partners Virtual Consumer Cannabis Conference
9/25/2020
Schwazze, formerly operating as Medicine Man Technologies, Inc. (OTCQX: SHWZ) (“Schwazze” or “the Company"), announced today that Justin Dye, Chief Executive Officer, and Nancy Huber, Chief Financial Officer, will be hosting meetings at the Alliance Global Partners Virtual Consumer Cannabis Conference on Tuesday, September 29, 2020.
-
BioDuro and Sundia Partner as an Industry Leading Contract Research, Development and Manufacturing Organization
9/25/2020
BioDuro, a global life science research and development organization backed by Advent International (“Advent”), and Sundia, a leading contract research and manufacturing organization, today announced that they have partnered to create one of the largest CRDMOs (contract rese
-
European Commission Grants Marketing Authorization for Jyseleca® ▼ (Filgotinib) for the Treatment of Adults With Moderate to Severe Active Rheumatoid Arthritis
9/25/2020
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced that the European Commission (EC) has granted marketing authorization for Jyseleca® (filgotinib 200 mg and 100 mg tablets), a once-daily, oral,
-
Vigil Health Solutions Announces Normal Course Issuer Bid
9/25/2020
Vigil Health Solutions Inc. (“Vigil” or the “Company”) (TSX-VEN: VGL) announced today that the TSX Venture Exchange (the “Exchange”) has accepted a notice of intention to make a normal course issuer bid (the “Bid”).
-
Curative Researchers Initiate Research Study to Test Efficacy of Self-Collected COVID-19 Tests
9/25/2020
COVID-19 testing startup Curative, Inc. today announced the launch of a new COVID-19 study in the City of San Antonio.
-
National Safety Council Urges Biden and Trump Campaigns to Include Opioid Overdose Prevention as Part of COVID-19 Recovery Plans
9/25/2020
With more than 40 states reporting increases in fatal opioid overdoses, the National Safety Council is urging both the Biden and Trump campaigns to include opioid overdose prevention as part of their COVID-19 recovery plans.
-
PMV Pharma Announces Pricing of Initial Public Offering
9/25/2020
PMV Pharmaceuticals, Inc., a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations, today announced the pricing of its initial public offering of 11,765,000 shares of common stock at a public offering price of $18.00 per share